Anoro contains which two pharmacologic classes?

Anoro contains which two pharmacologic classes?

• A. Short-acting beta-agonist and short-acting muscarinic antagonist
• B. Long-acting muscarinic antagonist and long-acting beta-agonist
• C. Inhaled corticosteroid and long-acting beta-agonist
• D. Long-acting beta-agonist and short-acting muscarinic antagonist

Answer: (B)

Anoro combines two long-acting bronchodilators: a long-acting muscarinic antagonist and a long-acting beta-agonist. Specifically, umeclidinium works as a LAMA, blocking muscarinic receptors on airway smooth muscle to prevent acetylcholine-induced constriction, while vilanterol acts as a LABA, stimulating beta-2 receptors to relax smooth muscle and keep airways open. Together, they provide sustained bronchodilation for COPD maintenance. It does not contain short-acting agents or inhaled corticosteroids, which is why the pairing is best described as a long-acting muscarinic antagonist and a long-acting beta-agonist.

Anoro combines two long-acting bronchodilators: a long-acting muscarinic antagonist and a long-acting beta-agonist. Specifically, umeclidinium works as a LAMA, blocking muscarinic receptors on airway smooth muscle to prevent acetylcholine-induced constriction, while vilanterol acts as a LABA, stimulating beta-2 receptors to relax smooth muscle and keep airways open. Together, they provide sustained bronchodilation for COPD maintenance. It does not contain short-acting agents or inhaled corticosteroids, which is why the pairing is best described as a long-acting muscarinic antagonist and a long-acting beta-agonist.